细胞与基因治疗药物警戒:风险管理与长期随访的演变挑战
本综述聚焦CAR-T细胞、CRISPR基因编辑及下一代病毒与非病毒递送平台等细胞与基因治疗,讨论其免疫并发症、基因毒性及器官特异性毒性等安全性挑战,并关注非典型表现、临床试验安全性捕获不足及全球长期随访基础设施差异。核心是提出风险自适应、数字化赋能的药物警戒模型,整合真实世界数据、人工智能信号检测及儿科至成人无缝随访,以主动保护患者并支持创新。
要点
- 细胞与基因治疗存在免疫并发症、基因毒性及器官特异性毒性等安全性挑战
- 临床试验安全性捕获存在不足,全球长期随访基础设施存在差异
- 风险自适应数字化药物警戒模型整合真实世界数据与人工智能信号检测
核心结论
- 细胞与基因治疗具有治愈潜力但伴随长期安全性挑战,需将药物警戒定位为治疗格局中主动和预测性基础。
研究设计与样本
- 这是一篇综述,分析细胞与基因治疗相关毒性范围,并探讨风险自适应、数字化赋能的药物警戒模型。
主要发现
- 相关毒性包括免疫并发症、基因毒性及器官特异性效应,需关注非典型表现、临床试验安全性捕获不足和全球长期随访基础设施差异。
临床怎么用
- 建议采用整合安全仪表盘、儿科过渡路线图和预测性监测工具,以改善申办者、监管机构和临床站点之间的协调。
- 建议将风险评估与缓解策略与风险管理计划对齐,并利用可穿戴生物传感器、电子患者报告结局和多组学标志物进行近实时安全监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell and gene therapies, including CAR T-cells, CRISPR-based genome editing, and next-generation viral and non-viral delivery platforms, are transforming treatment paradigms across cancer, rare genetic disorders, immune dysregulation, and neurodegenerative disease. These therapies offer curative potential but also present safety challenges owing to prolonged biological activity, systemic immune engagement, and lasting genomic alterations. This review examines the range of related toxicities, including immune complications, genotoxicity, and organ-specific effects, with attention to atypical presentations, gaps in clinical trial safety capture, and disparities in global long-term follow-up infrastructure. Central to our analysis is a risk-adaptive, digitally enabled pharmacovigilance model that incorporates real-world data, artificial intelligence-based signal detection, and seamless pediatric-to-adult follow-up to proactively protect patients while supporting innovation. Integrated safety dashboards, pediatric transition roadmaps, and predictive monitoring tools are proposed as practical solutions to improve coordination among sponsors, regulators, and clinical sites. We also outline best practices for aligning risk evaluation and mitigation strategies with risk management plans and examine how wearable biosensors, electronic patient-reported outcomes, and multi-omics biomarkers contribute to near real-time safety surveillance. Ethical priorities such as informed consent, data privacy, and equitable access are addressed throughout. By positioning pharmacovigilance as a proactive and predictive foundation within the therapeutic landscape, this review offers a forward-looking blueprint to advance innovation while ensuring long-term patient safety.
引用
- Youssef E, Weddle K, Zimmerman L, et al. Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up. Drug Saf. 2025. PMID: 40783602. doi:10.1007/s40264-025-01596-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。